Profile
Ms. Felicia Amilcar, CFA MBA, is Head of Risk Management & Compliance at Fondaction Le Fonds De Développement De La Csn Pour La Co. She joined the firm in 2010.
Ms. Amilcar was previously employed as Secretary by KLOX Technologies, Inc. and an Analyst by Caisse de dépôt et placement du Québec.
She also served on the board at Neurochem, Inc.
Ms. Amilcar received her undergraduate degree from the University of Montréal and an MBA from the University of Montréal.
Former positions of Felicia Amilcar
| Companies | Position | End |
|---|---|---|
| KLOX TECHNOLOGIES INC | Corporate Secretary | 31/12/2009 |
| BELLUS HEALTH | Corporate Officer/Principal | 31/12/2007 |
The Caisse de dépôt et placement du Québec
 The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | Corporate Officer/Principal | 28/02/2004 |
Training of Felicia Amilcar
| University of Montréal | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
The Caisse de dépôt et placement du Québec
The Caisse de dépôt et placement du Québec Investment ManagersFinance The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year. | Finance |
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
KLOX Technologies, Inc.
 KLOX Technologies, Inc. Medical SpecialtiesHealth Technology KLOX Technologies, Inc. designs and develops therapeutic and cosmetic products. The firm offers fluorescence biomodulation technology. The company was founded by Francesco Bellini in 2007 and is headquartered in Laval, Canada. | Health Technology |
- Stock Market
- Insiders
- Felicia Amilcar
